OXURION - Oxurion announces the signing of a binding agreement to acquire French biometrics specialist Axiodis CRO ...

CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company focused on the development of innovative therapies, announces the signing of a binding ...

Q1 2025 Earnings Call Transcript May 11, 2025 Operator: Greetings, and welcome to KORU Medical Systems First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this ...

Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

Objective This clinical study aimed to evaluate the clinical performance of an alkasite-based bioactive material by comparing it with a resin composite (RC) in the restoration of Class II cavities ...

A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential ...

IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward ...

Share on Pinterest Wegovy resolved liver inflammation in nearly two-thirds of participants in a major clinical trial, twice the rate seen with placebo. Steve Christo-Corbis/Getty Images Wegovy ...

A supportive government, modern infrastructure and easily accessible patient population are helping this Asian nation become a top location for clinical trial research. South Korea, a country in ...

The UK is paving the way for medical advancement with the launch of a first-of-its-kind clinical trial of a vaccine that doesn't require refrigeration. This could potentially revolutionise vaccine ...

A young woman is expressing her gratitude for a lifesaving clinical trial, while doctors hold their breath over the potential for federal funding cuts. After years of surgery, chemotherapy and ...

With this CNES approval, the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is cleared ...